Diagnostic Technology Advancements for Neuroendocrine Tumor Mapping Resulted in Dramatic Shifts in Access to Theranostics Care
A new study from the Neiman Institute found that the introduction of PET-based Gallium-68 DOTATATE/DOTATOC radiotracers for imaging neuroendocrine tumors created substantial differences in patient access during its first four years of use. Compared with the older imaging agent, Indium-111 pentetreotide (Octreoscan™), patients in small town-rural areas traveled 134.9 additional miles on average to access Gallium-68 DOTATATE/DOTATOC. The study, published in JACR, analyzed 3,365 claims for neuroendocrine tumor radiotracers. Read More